During the last session, Replimune Group Inc. (NASDAQ:REPL)’s traded shares were 0.31 million, with the beta value of the company hitting 2.37. At the end of the trading day, the stock’s price was $30.99, reflecting an intraday loss of -5.60% or -$1.84. The 52-week high for the REPL share is $54.79, that puts it down -76.8 from that peak though still a striking 10.75% gain since the share price plummeted to a 52-week low of $27.66. The company’s market capitalization is $1.42B, and the average intraday trading volume over the past 10 days was 0.31 million shares, and the average trade volume was 214.10K shares over the past three months.
Replimune Group Inc. (REPL) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.60. REPL has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 10 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.54.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Replimune Group Inc. (REPL) registered a -5.60% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.60% in intraday trading to $30.99 this Wednesday, 11/24/21, hitting a weekly high. The stock’s 5-day price performance is -6.85%, and it has moved by 6.83% in 30 days. Based on these gigs, the overall price performance for the year is -36.10%. The short interest in Replimune Group Inc. (NASDAQ:REPL) is 2.05 million shares and it means that shorts have 9.84 day(s) to cover.
The consensus price target of analysts on Wall Street is $54.40, which implies an increase of 43.03% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $49.00 and $64.00 respectively. As a result, REPL is trading at a discount of -106.52% off the target high and -58.12% off the low.
Replimune Group Inc. (REPL) estimates and forecasts
Statistics show that Replimune Group Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Replimune Group Inc. (REPL) shares have gone down -19.72% during the last six months, with a year-to-date growth rate less than the industry average at -29.71% against 7.90. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to shrink -17.40% this quarter and then drop -25.00% in the quarter after that.
While earnings are projected to return -13.80% in 2021.
Replimune Group Inc. is due to release its next quarterly earnings between August 05 and August 09. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Replimune Group Inc. (NASDAQ:REPL)’s Major holders
Replimune Group Inc. insiders own 8.82% of total outstanding shares while institutional holders control 94.33%, with the float percentage being 103.46%. Price (T.Rowe) Associates Inc is the largest shareholder of the company, while 174 institutions own stock in it. As of Jun 29, 2021, the company held over 5.07 million shares (or 10.84% of all shares), a total value of $194.77 million in shares.
The next largest institutional holding, with 5.01 million shares, is of Omega Fund Management (US) Inc.’s that is approximately 10.71% of outstanding shares. At the market price on Jun 29, 2021, these shares were valued at $192.42 million.
Also, the Mutual Funds coming in first place with the largest holdings of Replimune Group Inc. (REPL) shares are Price (T.Rowe) New Horizons Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. Data provided on Jun 29, 2021 indicates that Price (T.Rowe) New Horizons Fund owns about 1.66 million shares. This amounts to just over 3.55 percent of the company’s overall shares, with a $63.85 million market value. The same data shows that the other fund manager holds slightly less at 1.09 million, or about 2.34% of the stock, which is worth about $32.38 million.